Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EPS (Weighted Average and Diluted): 2022-2025

Historic EPS (Weighted Average and Diluted) for ARS Pharmaceuticals (SPRY) over the last 4 years, with Sep 2025 value amounting to -$0.52.

  • ARS Pharmaceuticals' EPS (Weighted Average and Diluted) fell 160.00% to -$0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.82, marking a year-over-year decrease of 60.78%. This contributed to the annual value of $0.08 for FY2024, which is 114.04% up from last year.
  • ARS Pharmaceuticals' EPS (Weighted Average and Diluted) amounted to -$0.52 in Q3 2025, which was down 13.04% from -$0.46 recorded in Q2 2025.
  • ARS Pharmaceuticals' EPS (Weighted Average and Diluted)'s 5-year high stood at $0.51 during Q4 2024, with a 5-year trough of -$0.52 in Q3 2025.
  • For the 3-year period, ARS Pharmaceuticals' EPS (Weighted Average and Diluted) averaged around -$0.17, with its median value being -$0.16 (2023).
  • Per our database at Business Quant, ARS Pharmaceuticals' EPS (Weighted Average and Diluted) surged by 828.57% in 2024 and then crashed by 253.85% in 2025.
  • ARS Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.39 in 2022, then soared by 81.89% to -$0.07 in 2023, then soared by 828.57% to $0.51 in 2024, then tumbled by 160.00% to -$0.52 in 2025.
  • Its EPS (Weighted Average and Diluted) stands at -$0.52 for Q3 2025, versus -$0.46 for Q2 2025 and -$0.35 for Q1 2025.